| pubmed-article:7988386 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7988386 | lifeskim:mentions | umls-concept:C0015780 | lld:lifeskim |
| pubmed-article:7988386 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:7988386 | lifeskim:mentions | umls-concept:C2698297 | lld:lifeskim |
| pubmed-article:7988386 | lifeskim:mentions | umls-concept:C0596763 | lld:lifeskim |
| pubmed-article:7988386 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:7988386 | pubmed:dateCreated | 1995-1-9 | lld:pubmed |
| pubmed-article:7988386 | pubmed:abstractText | para-Nitrotoluene (p-nitrotoluene) is used primarily as an intermediate in the production of various dyes, explosives, pharmaceuticals, and in the production of rubber and agricultural products. Previous investigations indicated that p-nitrotoluene was mutagenic in the Ames Test and that other mono-substituted nitrotoluenes bound covalently to hepatic macromolecules. The objective of these studies was to evaluate the potential immunotoxicity of p-nitrotoluene in mice exposed by the oral route. Mice exposed to p-nitrotoluene (200-600 mg/kg) daily for 14 days showed modest dose-dependent increases in liver and spleen weights. The livers of mice exposed subchronically to 400 and 600 mg/kg showed a mild to moderate swelling of the hepatocytes adjacent to the central veins; this swelling appeared to be reversible and there was no evidence of necrosis. The proportion of monocytes in blood was decreased in mice treated with p-nitrotoluene or toluene. Serum chemistries, bone marrow cellularity and the number of CFU-M and CFU-GM were unaffected. Immunologic investigations showed p-nitrotoluene suppressed the IgM response to sRBC and the DHR response to KLH. There was a 24% decrease in the percentage of CD4+ T lymphocytes in the spleen. There was no dose-dependent alteration of peritoneal macrophage numbers or differential count, unstimulated natural killer cell activity, response to B cell mitogen LPS, C3 activity or interferon levels. Exposure of mice to p-nitrotoluene decreased resistance to Listeria monocytogenes but not to Streptococcus pneumoniae, Plasmodium yoelii or the B16F10 melanoma, and increased resistance to the PYB6 tumor. These studies indicated that the immune system is an important target for toxicity of p-nitrotoluene. The decreased host resistance to L. monocytogenes can be attributed to the decrease in T lymphocytes and to a decreased delayed hypersensitivity response to KLH. | lld:pubmed |
| pubmed-article:7988386 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7988386 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7988386 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7988386 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7988386 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7988386 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7988386 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7988386 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7988386 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7988386 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7988386 | pubmed:issn | 0148-0545 | lld:pubmed |
| pubmed-article:7988386 | pubmed:author | pubmed-author:LusterM IMI | lld:pubmed |
| pubmed-article:7988386 | pubmed:author | pubmed-author:BrownR DRD | lld:pubmed |
| pubmed-article:7988386 | pubmed:author | pubmed-author:BradleyS GSG | lld:pubmed |
| pubmed-article:7988386 | pubmed:author | pubmed-author:SternMM | lld:pubmed |
| pubmed-article:7988386 | pubmed:author | pubmed-author:HolsappleM... | lld:pubmed |
| pubmed-article:7988386 | pubmed:author | pubmed-author:BurnsL ALA | lld:pubmed |
| pubmed-article:7988386 | pubmed:author | pubmed-author:WhiteK LKLJr | lld:pubmed |
| pubmed-article:7988386 | pubmed:author | pubmed-author:FuchsB ABA | lld:pubmed |
| pubmed-article:7988386 | pubmed:author | pubmed-author:McCayJ AJA | lld:pubmed |
| pubmed-article:7988386 | pubmed:author | pubmed-author:MusgroveD LDL | lld:pubmed |
| pubmed-article:7988386 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7988386 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:7988386 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7988386 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:7988386 | pubmed:pagination | 317-58 | lld:pubmed |
| pubmed-article:7988386 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:meshHeading | pubmed-meshheading:7988386-... | lld:pubmed |
| pubmed-article:7988386 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:7988386 | pubmed:articleTitle | Immunotoxicity of mono-nitrotoluenes in female B6C3F1 mice: I. Para-nitrotoluene. | lld:pubmed |
| pubmed-article:7988386 | pubmed:affiliation | Department of Pharmacology, Virginia Commonwealth University, Richmond 23298. | lld:pubmed |
| pubmed-article:7988386 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7988386 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:7988386 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
